Teijin To Partner With Amgen For Autoimmune Blockbuster Drugs
This article was originally published in PharmAsia News
Teijin plans a partnership with Amgen to develop drugs for autoimmune diseases, including rheumatoid arthritis, drawing on the Japan drug maker's basic protein research.
You may also be interested in...
Work and movement-related restrictions are affecting the ability of companies to provide a timely response to questions relating to their prequalification dossiers.
Celltrion has accelerated the development of its antiviral treatment for COVID-19 and aims to launch a rapid self-testing kit that could provide results within 15-20 minutes. The Korean firm also plans to develop a ‘super antibody’ to prepare for potential future pandemic situations.